Peptisyntha Expands its Production Capacity in Brussels, Belgium
28 February 2007
Peptisyntha SA has launched the expansion of its pilot-scale capacity for the production of cGMP bulk peptides based on solution phase technology at its production plant in Brussels, Belgium. The expansion includes an additional pilot HPLC purification unit, an additional pilot freeze-dryer and an additional pilot plant for the chemical synthesis of peptides. All these new units are scheduled to be fully operational during 2007. Peptisyntha has already completed construction and validation of its new cGMP QC laboratories on the same site in 2006.
The current expansion of the cGMP production capacity in Brussels follows the recent expansion of the solid-phase peptide synthesis capacity implemented by Peptisyntha Inc. in Torrance, USA, which came on stream in 2006. Peptisyntha SA and Peptisyntha Inc. are fully owned subsidiaries of the Solvay Group. Details are available at on our website
"This additional capacity will allow us to better serve our growing customer-base and to manage the fast growing pipeline of projects currently undertaken at Peptisyntha for peptide APIs in all stages of clinical development", said Pierre Barthélemy, general manager of Solvay Peptides.
The peptide business makes a significant contribution to the overall platform of technologies of Solvay Organics, a business unit focused on high added-value organic chemical specialties that serves a wide array of market segments with innovative molecules, materials and solutions for novel applications.
SOLVAY is an international chemical and pharmaceutical group with headquarters in Brussels. It employs some 29,000 people in 50 countries. In 2006, its consolidated sales amounted to €9.4 billion, generated by its three sectors of activity: chemicals, plastics and pharmaceuticals. Solvay (Euronext : SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels. Details are available at www.solvay.com.
